Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
Status:
Completed
Trial end date:
2016-07-12
Target enrollment:
Participant gender:
Summary
This randomized phase I trial studies the side effects and best dose of dinaciclib and Akt
inhibitor MK2206 in treating patients with pancreatic cancer that cannot be removed by
surgery. Dinaciclib and Akt inhibitor MK2206 may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth.